Gustafsson, B.I., Kidd, M., Chan, A., Malfertheiner, M.V. & Modlin, I.M.
Bronchopulmonary neuroendocrine tumors. Cancer
113, 5–21 (2008).
Lung tumours with neuroendocrine differentiation. Eur. J. Cancer
(suppl. 1), 251–266 (2009).
van Meerbeeck, J.P., Fennell, D.A. & De Ruysscher, D.K.
Small-cell lung cancer. Lancet
378, 1741–1755 (2011).
et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat. Med.
17, 1504–1508 (2011).
World Health Organization. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (eds. Travis, W.D., Brambilla, E., Müller-Hermilink, H.K. & Harris, C.C.) 344 (IARC Press, Lyon, France, 2004).
Tiseo, M. & Ardizzoni, A.
Current status of second-line treatment and novel therapies for small cell lung cancer. J. Thorac. Oncol.
2, 764–772 (2007).
et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med.
363, 1693–1703 (2010).
et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.
350, 2129–2139 (2004).
et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science
304, 1497–1500 (2004).
Pao, W. & Chmielecki, J.
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer
10, 760–774 (2010).
et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA
101, 13306–13311 (2004).
et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature
448, 561–566 (2007).
et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol.
30, 863–870 (2012).
et al. KIF5B-RET fusions in lung adenocarcinoma. Nat. Med.
18, 375–377 (2012).
et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med.
18, 382–384 (2012).
et al. RET, ROS1 and ALK fusions in lung cancer. Nat. Med.
18, 378–381 (2012).
et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One
6, e20351 (2011).
et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov.
1, 78–89 (2011).
et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med.
2, 62ra93 (2010).
et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet.
41, 1238–1242 (2009).
et al. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene
25, 130–138 (2006).
Wistuba, I.I., Gazdar, A.F. & Minna, J.D.
Molecular genetics of small cell lung carcinoma. Semin. Oncol.
28, 3–13 (2001).
et al. Activation of myc gene family in human lung carcinomas and during heterotransplantation into nude mice. Cancer Res.
51, 2566–2571 (1991).
et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res.
65, 5561–5570 (2005).
et al. Array comparative genomic hybridization–based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc. Natl. Acad. Sci. USA
107, 13040–13045 (2010).
Hassan, M.I., Naiyer, A. & Ahmad, F.
Fragile histidine triad protein: structure, function, and its association with tumorogenesis. J. Cancer Res. Clin. Oncol.
136, 333–350 (2010).
et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell
19, 244–256 (2011).
et al. Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev.
25, 1470–1475 (2011).
et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell
4, 181–189 (2003).
et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res.
70, 3877–3883 (2010).
et al. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell
19, 754–764 (2011).
Iaquinta, P.J. & Lees, J.A.
Life and death decisions by the E2F transcription factors. Curr. Opin. Cell Biol.
19, 649–657 (2007).
et al. The genomic complexity of primary human prostate cancer. Nature
470, 214–220 (2011).
et al. Initial genome sequencing and analysis of multiple myeloma. Nature
471, 467–472 (2011).
et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature
464, 999–1005 (2010).
et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science
330, 228–231 (2010).
et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature
463, 191–196 (2010).
et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature
463, 184–190 (2010).
et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature
475, 101–105 (2011).
The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature
474, 609–615 (2011).
et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature
469, 539–542 (2011).
Karro, J.E., Peifer, M., Hardison, R.C., Kollmann, M. & von Grunberg, H.H.
Exponential decay of GC content detected by strand-symmetric substitution rates influences the evolution of isochore structure. Mol. Biol. Evol.
25, 362–374 (2008).
Progress and challenges in selected areas of tobacco carcinogenesis. Chem. Res. Toxicol.
21, 160–171 (2008).
Rodin, S.N. & Rodin, A.S.
Origins and selection of p53 mutations in lung carcinogenesis. Semin. Cancer Biol.
15, 103–112 (2005).
et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc. Natl. Acad. Sci. USA
87, 2775–2779 (1990).
et al. Variable mutations of the RB gene in small-cell lung carcinoma. Oncogene
5, 1713–1717 (1990).
et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer
91, 355–358 (2004).
Wong, K., Park, H.T., Wu, J.Y. & Rao, Y.
Slit proteins: molecular guidance cues for cells ranging from neurons to leukocytes. Curr. Opin. Genet. Dev.
12, 583–591 (2002).
et al. Slit-Robo signaling induces malignant transformation through Hakai-mediated E-cadherin degradation during colorectal epithelial cell carcinogenesis. Cell Res.
21, 609–626 (2011).
et al. Inadequate lung development and bronchial hyperplasia in mice with a targeted deletion in the Dutt1/Robo1 gene. Proc. Natl. Acad. Sci. USA
98, 15062–15066 (2001).
et al. SLIT2 attenuation during lung cancer progression deregulates β-catenin and E-cadherin and associates with poor prognosis. Cancer Res.
70, 543–551 (2010).
et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell
20, 289–299 (2011).
et al. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell
147, 554–564 (2011).
Holmberg, J., Clarke, D.L. & Frisen, J.
Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature
408, 203–206 (2000).
et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene
12, 1565–1569 (1996).
et al. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature
451, 846–850 (2008).
et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature
471, 189–195 (2011).
et al. Mutations and deletions of the CBP gene in human lung cancer. Clin. Cancer Res.
11, 512–519 (2005).
et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature
476, 298–303 (2011).
et al. CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia
26, 1797–1803 (2012).
et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature
471, 235–239 (2011).
et al. Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines. Genes Chromosom. Cancer
37, 121–131 (2003).
Ng, P.C. & Henikoff, S.
SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res.
31, 3812–3814 (2003).
et al. Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency. Cancer Cell
5, 177–189 (2004).
et al. Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development. Mol. Cell Biol.
26, 789–809 (2006).
et al. CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation. EMBO J.
29, 3660–3672 (2010).
et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N. Engl. J. Med.
329, 909–914 (1993).
The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res.
32, 959–976 (2004).
et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene
17, 475–479 (1998).
et al. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res.
60, 3147–3151 (2000).
et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res.
68, 6913–6921 (2008).
Zakowski, M.F., Ladanyi, M. & Kris, M.G.
EGFR mutations in small-cell lung cancers in patients who have never smoked. N. Engl. J. Med.
355, 213–215 (2006).
et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med.
3, 75ra26 (2011).
Gu, W., Shi, X.L. & Roeder, R.G.
Synergistic activation of transcription by CBP and p53. Nature
387, 819–823 (1997).
Brooks, C.L. & Gu, W.
Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol.
15, 164–171 (2003).
et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev.
12, 2831–2841 (1998).
Kruse, J.P. & Gu, W.
Modes of p53 regulation. Cell
137, 609–622 (2009).
et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science
300, 342–344 (2003).
Lill, N.L., Grossman, S.R., Ginsberg, D., DeCaprio, J. & Livingston, D.M.
Binding and modulation of p53 by p300/CBP coactivators. Nature
387, 823–827 (1997).
et al. Signal transduction in neuronal migration: roles of GTPase activating proteins and the small GTPase Cdc42 in the Slit-Robo pathway. Cell
107, 209–221 (2001).
et al. Functional analysis of the p300 acetyltransferase domain: the PHD finger of p300 but not of CBP is dispensable for enzymatic activity. Nucleic Acids Res.
29, 4462–4471 (2001).
Li, H., Ruan, J. & Durbin, R.
Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res.
18, 1851–1858 (2008).
Li, H. & Durbin, R.
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics
25, 1754–1760 (2009).
et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature
455, 1069–1075 (2008).
et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod. Pathol.
23, 1061–1067 (2010).
et al. Definition of a fluorescence in situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod. Pathol. published online, doi:10.1038/modpathol.2012.102 (8 June 2012).
Laframboise, T., Harrington, D. & Weir, B.A.
PLASQ: a generalized linear model–based procedure to determine allelic dosage in cancer cells from SNP array data. Biostatistics
8, 323–336 (2007).
Olshen, A.B., Venkatraman, E.S., Lucito, R. & Wigler, M.
Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics
5, 557–572 (2004).
et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J. Clin. Invest.
119, 1727–1740 (2009).
et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One
6, e19601 (2011).